Top-Rated StocksTop-RatedNASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Forecast, Price & News $119.93 +0.38 (+0.32%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$119.65▼$121.8250-Day Range$102.50▼$122.8652-Week Range$100.15▼$159.89Volume553,449 shsAverage Volume756,488 shsMarket Capitalization$10.55 billionP/E RatioN/ADividend YieldN/APrice Target$173.70 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Sarepta Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside44.8% Upside$173.70 Price TargetShort InterestBearish5.24% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment1.03Based on 4 Articles This WeekInsider TradingAcquiring Shares$4.79 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($9.21) to ($1.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.30 out of 5 starsMedical Sector289th out of 963 stocksPharmaceutical Preparations Industry120th out of 458 stocks 3.5 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $173.70, Sarepta Therapeutics has a forecasted upside of 44.8% from its current price of $119.93.Amount of Analyst CoverageSarepta Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.24% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Sarepta Therapeutics has recently increased by 4.06%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 2.8 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sarepta Therapeutics this week, compared to 7 articles on an average week.Search Interest23 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 5% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have bought 199.45% more of their company's stock than they have sold. Specifically, they have bought $4,793,533.00 in company stock and sold $1,600,800.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions91.82% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow in the coming year, from ($9.21) to ($1.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -11.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -11.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 27.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sarepta Therapeutics (NASDAQ:SRPT) StockSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More SRPT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRPT Stock News HeadlinesSeptember 8, 2023 | insidertrades.comInsiders Are Buying These 2 Stocks (SRPT)September 23, 2023 | money.usnews.comSarepta Therapeutics IncSeptember 24, 2023 | Legacy Research (Ad)The Real Reason They Murdered JFK?Some people believe JFK was murdered because of his executive order 11110 that would have reduced the power of the Federal Reserve. Regardless if that’s true or not… The Fed is now involved in a new controversy that could have drastic consequences for the US dollar.September 16, 2023 | fool.comSarepta Therapeutics (NASDAQ: SRPT)September 15, 2023 | barrons.comS&P 500 Futures Climb in Premarket Trading; Sarepta Therapeutics, Unity Software LeadSeptember 14, 2023 | finance.yahoo.com2 Top Growth Stocks to Buy With $500September 14, 2023 | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 13, 2023 | seekingalpha.comSarepta: Broad Label Expansion Possible With Q4 2023 CatalystSeptember 24, 2023 | Legacy Research (Ad)The Real Reason They Murdered JFK?Some people believe JFK was murdered because of his executive order 11110 that would have reduced the power of the Federal Reserve. Regardless if that’s true or not… The Fed is now involved in a new controversy that could have drastic consequences for the US dollar.September 7, 2023 | finance.yahoo.comSarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic YearSeptember 5, 2023 | finance.yahoo.comSarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 1, 2023 | finance.yahoo.comSarepta Therapeutics (SRPT) Up 12.7% Since Last Earnings Report: Can It Continue?August 30, 2023 | markets.businessinsider.comQuest Diagnostics Says FDA Grants Breakthrough Designation For Adeno-associated Virus TestAugust 30, 2023 | finance.yahoo.comQuest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) TestAugust 30, 2023 | finance.yahoo.comFibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%August 27, 2023 | finance.yahoo.comSRPT Aug 2023 102.000 callAugust 23, 2023 | finance.yahoo.comIs Sarepta Therapeutics Stock a Top Growth Vehicle?August 16, 2023 | seekingalpha.comSarepta Eyes Broadened Label For ELEVIDYS Amid Progress (Rating Upgrade)August 14, 2023 | benzinga.comMassive Insider Trade At Sarepta TherapeuticsAugust 14, 2023 | msn.comTake a Look at Sarepta’s (NASDAQ:SRPT) Latest Insider TradeAugust 13, 2023 | finance.yahoo.comSarepta Therapeutics' Michael Chambers Acquires 19% More StockAugust 4, 2023 | finance.yahoo.comFDA-approved gene therapy invented at Nationwide Children's carries a $3.2M price tag. Here's why.August 3, 2023 | finance.yahoo.comSarepta (SRPT) Q2 Loss Narrower Than Expected, Sales MissAugust 3, 2023 | markets.businessinsider.comSarepta Therapeutics (SRPT) Gets a Buy from Mizuho SecuritiesAugust 2, 2023 | finance.yahoo.comSarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsAugust 2, 2023 | markets.businessinsider.comSarepta Therapeutics Q2 Loss Decreases, beats estimatesAugust 2, 2023 | finance.yahoo.comSarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue EstimatesSee More Headlines Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Company Calendar Last Earnings8/02/2023Today9/24/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,162Year Founded1980Price Target and Rating Average Stock Price Forecast$173.70 High Stock Price Forecast$223.00 Low Stock Price Forecast$125.00 Forecasted Upside/Downside+44.8%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($10.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-703,490,000.00 Net Margins-90.46% Pretax Margin-88.20% Return on Equity-91.22% Return on Assets-16.60% Debt Debt-to-Equity Ratio1.67 Current Ratio4.96 Quick Ratio4.50 Sales & Book Value Annual Sales$933.01 million Price / Sales11.31 Cash FlowN/A Price / Cash FlowN/A Book Value$4.39 per share Price / Book27.32Miscellaneous Outstanding Shares88,000,000Free Float81,488,000Market Cap$10.55 billion OptionableOptionable Beta0.94 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Douglas S. Ingram Esq. (Age 60)Pres, CEO & Director Comp: $1.62MMr. Ian Michael Estepan (Age 47)Exec. VP & CFO Comp: $917.53kDr. Louise R. Rodino-Klapac Ph.D. (Age 45)Exec. VP, Chief Scientific Officer and Head of R&D Comp: $1.04MMr. Ryan E. Brown J.D. (Age 45)Exec. VP, Gen. Counsel & Corp. Sec. Comp: $823.36kMr. Bilal Arif (Age 51)Exec. VP & Chief Technical Operations Officer Mary JenkinsSr. Mang. of Investor RelationsMs. Alison NasisiExec. VP & Chief People OfficerDr. Diane L. Berry Ph.D.Exec. VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExec. VP & Chief Customer OfficerMr. Will TiltonSr. VP, Head of Strategy & Chief of StaffMore ExecutivesKey CompetitorsUnited TherapeuticsNASDAQ:UTHRLegend BiotechNASDAQ:LEGNVerona PharmaNASDAQ:VRNADr. Reddy's LaboratoriesNYSE:RDYTeva Pharmaceutical IndustriesNYSE:TEVAView All CompetitorsInsiders & InstitutionsBarclays PLCSold 55,085 shares on 9/21/2023Ownership: 0.453%CGC Financial Services LLCBought 913 shares on 9/13/2023Ownership: 0.001%Yarbrough Capital LLCBought 2,790 shares on 8/25/2023Ownership: 0.003%Perceptive Advisors LLCSold 179,784 shares on 8/24/2023Ownership: 0.092%Wolverine Trading LLCSold 39,700 shares on 8/23/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SRPT Stock - Frequently Asked Questions Should I buy or sell Sarepta Therapeutics stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SRPT shares. View SRPT analyst ratings or view top-rated stocks. What is Sarepta Therapeutics' stock price forecast for 2023? 15 equities research analysts have issued 12-month target prices for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $125.00 to $223.00. On average, they anticipate the company's share price to reach $173.70 in the next twelve months. This suggests a possible upside of 44.8% from the stock's current price. View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts. How have SRPT shares performed in 2023? Sarepta Therapeutics' stock was trading at $129.58 at the beginning of 2023. Since then, SRPT stock has decreased by 7.4% and is now trading at $119.93. View the best growth stocks for 2023 here. When is Sarepta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our SRPT earnings forecast. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($1.89) by $1.62. The biotechnology company had revenue of $261.20 million for the quarter, compared to analysts' expectations of $255.99 million. Sarepta Therapeutics had a negative net margin of 90.46% and a negative trailing twelve-month return on equity of 91.22%. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.65) EPS. What ETFs hold Sarepta Therapeutics' stock? ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Morningstar US Small Growth (MSGR), Global X Genomics & Biotechnology ETF (GNOM), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and American Century Mid Cap Growth Impact (MID). What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS). What is Sarepta Therapeutics' stock symbol? Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT." Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.25%), Bank of New York Mellon Corp (2.61%), State Street Corp (2.17%), Geode Capital Management LLC (1.58%), Casdin Capital LLC (1.15%) and Goldman Sachs Group Inc. (1.10%). Insiders that own company stock include Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sarepta Therapeutics' stock price today? One share of SRPT stock can currently be purchased for approximately $119.93. How much money does Sarepta Therapeutics make? Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $10.55 billion and generates $933.01 million in revenue each year. The biotechnology company earns $-703,490,000.00 in net income (profit) each year or ($10.31) on an earnings per share basis. How many employees does Sarepta Therapeutics have? The company employs 1,162 workers across the globe. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.Read More How can I contact Sarepta Therapeutics? Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038. This page (NASDAQ:SRPT) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.